Analysts See 489% Upside Potential

We recently published an article entitled 13 best multiple shares to invest in now. Capricor Therapeutics, Inc. (NASDAQ: CAPR) is one of the shares covered in this article. Wall Street analyzes believe that CAPR has 489 % thunderstorms over the next 12 months.

The test tubes filled with Xosomes, which represent exosome treatments.

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company that specializes in developing cells based on cells and cells for muscle diseases and others. Its pioneering therapeutic filter, CAP-1002, in advanced clinical stages designed to treat muscle atrophy Duchenne (DMD), a severe genetic disorder that primarily affects muscles and heart. CAP-1002 is used by the cells derived from the heart (CDCS), which has been proven to adjust the immune system and reduce the accumulation of harmful tissues, known as fibrosis, in the heart. This unique approach emphasizes the company’s dedication to treating complex medical conditions through innovative science.

In addition to its work on CAP-1002, Capricor actively applies its Exosome platform, which mocks the possibilities of vesicles outside the cell for therapeutic applications. Cooperation with respected institutions such as the National Institutes of Health (NIH), the American Army’s Surgical Research Institute, Johns Hopkins University, and the Cedars-Sinai Medical Center represent its commitment to progress in research and development. These partnerships aim to expand the scope of CAPRICOR initiatives, including the development of vaccines and treatments for infectious diseases and unilateral disorders.

Capricor Therapeutics showed financial strength and strategic insight. For the fourth quarter of 2024, the company recorded revenues of $ 11.13 million, which contributed to its total annual revenue of $ 25.4 million. This growth is due to its pioneering efforts in cell therapy programs. With cash reserves amounting to $ 78 million, Capricor is well equipped to support continuous clinical trials and future marketing efforts, ensuring a sustainability in its ambitious endeavors.

In March, Reuters announced in an article in an article, Capricor Therapics (CAPR.O) announced that the US Food and Drug Administration (FDA) intends to assemble a committee of external experts to review the cellular therapy of the heart -related heart condition (DMD) before making a final decision. The company follows a complete regulatory approval to treat it in investigative cells, Deraoocel, as a potential treatment for patients with Duchenne muscle muscle disorders. In the aftermath of the news, the shares of the company decreased by approximately 15 %, and reached $ 10.11 in morning trading. However, Wall Street analysts visited Capricor prospects, and they recommended the arrow as a “strong purchase”. The 12 -month consensus price is targeted from May 13, 2025, 43.71 dollars, which reflects noticeable noticeable capabilities of 489.89 %.